Ticagrelor/Prasugrel as good as clopidogrel in Lowering 1-Year Mortality in STEMI Patients with Severe CKD: Study
A recent study published in BMC Nephrology evaluated the comparative effectiveness of ticagrelor/prasugrel versus clopidogrel in acute coronary syndrome (ACS) patients with chronic kidney disease (CKD). Researchers analyzed outcomes including rehospitalization, bleeding events, and mortality over 30 days and one year, with a focus on patients presenting with ST-elevation myocardial infarction (STEMI) and severely reduced kidney function (glomerular filtration rate [GFR] less than 30 ml/min).
Findings showed that during the initial 30-day period, there were no significant differences between the two groups in rates of rehospitalization, bleeding complications, or mortality, suggesting similar short-term safety profiles. However, for STEMI patients with severe CKD, ticagrelor/prasugrel use was associated with significantly lower 1-year mortality compared to clopidogrel, without an increase in bleeding risk.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.